Garioud Anne Louise de Barros, Nielsen Bettina Nygaard, Falcon Lars, Mondrup Frederik, Afshari Arash
Department of Anesthesiology, Juliane Marie Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Acta Anaesthesiol Scand. 2023 May;67(5):663-669. doi: 10.1111/aas.14212. Epub 2023 Feb 27.
Emergence agitation is a common clinical condition in children. Symptoms pertaining to the spectrum of early postoperative negative behavior typically occur upon emergence from anesthesia. Clonidine is an effective adjunctive agent for the prevention of emergence agitation in children, but evidence in the smallest age groups is sparse We aim to investigate the efficacy and safety of an intraoperative bolus of intravenous clonidine for preventing emergence agitation in children 3-12 months of age.
This is a randomized, placebo-controlled, double-blind trial. We will enroll 320 patients aged 3-12 months who have been scheduled for general anesthesia maintained with sevoflurane and opioid. The randomization is parallel and stratified by age group, sex, and site. The investigational medicinal product will be administered intravenously ~20 min before the anticipated end of the surgical procedure. The intervention is clonidine 3 μg/kg and placebo is isotonic saline in a corresponding volume.
The primary outcome is the incidence of emergence agitation as assessed on the Watcha scale, that is, any Watcha score >2 during participants' stay in the postanesthetic care unit. Secondary outcomes are the proportion of participants with postoperative pain, with postoperative nausea and vomiting, and a composite safety outcome. Statistical analysis will be conducted according to the Statistical Analysis Plan with the intention-to-treat population for our primary analyses.
The PREVENT AGITATION II trial will contribute valuable knowledge on efficacy for the prevention of emergence agitation and safety in infants.
苏醒期躁动是儿童常见的临床情况。与术后早期负面行为谱相关的症状通常在麻醉苏醒时出现。可乐定是预防儿童苏醒期躁动的有效辅助药物,但在最小年龄组中的证据较少。我们旨在研究术中静脉注射可乐定预防3至12个月龄儿童苏醒期躁动的有效性和安全性。
这是一项随机、安慰剂对照、双盲试验。我们将招募320名3至12个月龄计划接受七氟醚和阿片类药物维持全身麻醉的患者。随机分组为平行设计,并按年龄组、性别和手术部位进行分层。研究用药品将在预计手术结束前约20分钟静脉给药。干预药物为3μg/kg可乐定,安慰剂为相应体积的等渗盐水。
主要结局是根据Watcha量表评估的苏醒期躁动发生率,即在参与者留在麻醉后护理单元期间,任何Watcha评分>2。次要结局是术后疼痛、术后恶心和呕吐的参与者比例,以及综合安全结局。将根据统计分析计划对意向性治疗人群进行主要分析的统计分析。
PREVENT AGITATION II试验将为预防婴儿苏醒期躁动的有效性和安全性提供有价值的知识。